9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

New York Mortgage Trust, Inc. is a real estate investment trust, which engages in the acquisition, investment, finance, and management of mortgage-related single-family and multi-family residential assets. Its investment portfolio includes credit sensitive single-family and multi-family assets. The company was founded on September 26, 2003 and is headquartered in New York, NY.

Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by end of month RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced completion of a pre-specified interim analysis for the Phase 3 study of larazotide, referred to as CedLara® (Celiac disease Larazotide), for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. The interim analysis was conducted by an independent statistician, with the sole purpose of re-estimating the treatment group size required to detect a statistically significant clinical effect of larazotide, utilizing patient data from the study.

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, in San Diego, California. Attendance at the 2022 BIO International Convention is aligned with the Company's strategy to secure partners for the global and/or regional development and future commercialization of its advanced development stage assets, vurolenatide for short bowel syndrome and larazotide for celiac disease.

9 Meters Biopharma to Participate in the 2022 BIO International Convention

RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will host an exhibit at Digestive Disease Week (DDW) which takes place May 21-24, 2022, in San Diego, CA. 9 Meters will be located at booth #1625 in the exhibition hall at the San Diego Convention Center.

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that Matthew Bryant, PharmD, Vice President of Medical Affairs at 9 Meters, delivered a poster presentation at the American Thoracic Society (ATS) International Conference, taking place in San Francisco May 13 - 18, 2022. The presentation highlighted preclinical data investigating the use of larazotide, a tight junction regulator, to reduce lung fibrosis in an animal model of idiopathic pulmonary fibrosis (IPF).

9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis

On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June Cash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023 RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022. John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is an exciting time for 9 Meters.

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, and Celiac.com, a news, information, and support website for those on a gluten-free diet due to celiac disease or gluten sensitivity announced today a collaboration to further support clinical trial enrollment in 9 Meters' Phase 3 study known as CeDLara, for the drug candidate larazotide for celiac disease. 9 Meters' CeDLara study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 9 Meters' larazotide for adult patients with at least a six-month history of celiac disease who continue to experience gastrointestinal symptoms despite maintaining a gluten-free diet.

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease

RALEIGH, NC / ACCESSWIRE / April 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 16/781,304 is allowed.

9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions

RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021. John Temperato, President & CEO of 9 Meters Biopharma, commented: "2021 was an exceptionally productive year for 9 Meters as we significantly advanced our pipeline, particularly our lead assets vurolenatide for short bowel syndrome (SBS) and larazotide for celiac disease.

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021

RALEIGH, NC / ACCESSWIRE / March 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Maxim Group 2022 Virtual Growth Conference hosted by M-Vest on March 28 - 30, 2022. Maxim Group 2022 Virtual Growth Conference Presentation: Available for viewing on March 28 - 30, 2022 Webcast: https://m-vest.com/events/2022-virtual-growth-conference/p/nmtr The presentation will also be available in the events section of the 9 Meters website.

9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference

RALEIGH, NC / ACCESSWIRE / March 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022, at 10:00 a.m. (ET). The conference will take place on March 15-17, 2022, and is being held virtually.

9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference

RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today a collaboration with NYU Langone Health investigating the pre-clinical use of 9 Meters' gut-restricted tight junction regulator, NM-102, for an undisclosed autoimmune condition with a large unmet need. NM-102 is a peptide that is believed to mitigate the inflammatory responses that can occur when certain proteins from the gastrointestinal tract are aberrantly released into systemic circulation.

9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder

RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide (GLP-1) agonist in a Phase 2 trial for adults with short bowel syndrome (SBS), and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease. The vurolenatide Phase 2 trial known as the VIBRANT (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT) study, is a double-blind, multicenter, placebo-controlled parallel group study of the safety, efficacy, and tolerability of vurolenatide in adult patients with SBS.

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.

9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)

RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, Inc., will deliver a virtual presentation as part of the 2022 BIO CEO & Investor Conference taking place February 14-17, 2022. Registered attendees of the conference will have access to an on-demand presentation highlighting the Company's advanced pipeline and upcoming clinical milestones for vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome currently in a Phase 2 clinical study, and larazotide, its Phase 3 tight junction regulator for celiac disease.

9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference

RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 17/239,056 is allowed.

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors

Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer. "We're very pleased to have Ms.

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below: 11th Annual LifeSci Partners Corporate Access Event Wednesday, January 5th - Friday, January 7th Registration Link or submit 1x1 meeting requests HERE H.C.

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences

RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications. "We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma.

9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced the company has awarded an unrestricted educational grant to Carol Rees Parrish, M.S., RDN, a GI Nutrition Support Specialist to support a new educational website: SBSCurbside.

9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education

The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)

- Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 - - Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 - - Appointed Samantha Ventimiglia of Vertex to the Board of Directors - - Quarter ending cash of $53.6 million is expected to fund operations into 2023 - RALEIGH, NC / ACCESSWIRE / November 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today provided a business update and reported financial results for the third quarter ended September 30, 2021. Key Business Highlights Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for SBS expected in Q1 2022 Announced immuno-oncology collaboration with Gustave Roussy, building upon previously announced data highlighting NM-102's unique effect on GI biology In October, received issuance of patent on NM-102, a proprietary tight-junction microbiome modulator Poster presentation titled, "Therapeutic Candidate in Short Bowel Syndrome" at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting Announced partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger In August, announced collaboration with European Biomedical Research Institute of Salerno foundation for planned Phase 2 Study of larazotide for the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19.

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021

Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect IND-enabling pathway for NM-102 underway with indication selection anticipated in 2022 Composition of matter patent recently issued for NM-102, a unique gut-selective peptide RALEIGH, NC / ACCESSWIRE / November 10, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced a collaboration agreement with Gustave Roussy, a leading cancer center in Villejuif, France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into systemic circulation.

9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator

In-Person Dates: November 16th-17th Virtual Dates: November 18th-19th RALEIGH, NC / ACCESSWIRE / November 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato is scheduled to present at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in one-on-one meetings both in person on Tuesday and Wednesday November 16th/17th or virtually on Thursday and Friday November 18th/19th. Please see Live Presentation details below: 12th Annual Jefferies London Healthcare Conference Date: Wednesday, November 17th Time: 10:00 to 10:35 a.m.

9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

- Vurolenatide's half-life is consistent with twice-monthly dosing - - Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today presented pharmacokinetic data on its drug candidate vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in development for short bowel syndrome (SBS), at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting, being held in Las Vegas, Nevada through October 27, 2021. The data were sourced from the Phase 1b/2a clinical trial of vurolenatide in SBS patients (NCT04379856) that had initial top-line results reported in December 2020 and were highlighted in a poster presented by the company's chief medical officer, Patrick H.

9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting

News for 9 Meters Biopharma Stock (NMTR)